TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22989378

Group type: EXPERIMENTAL
Intervention: Natalizumab (NAT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA)
Number of subjects: 23
Study: 20214337

Group type: EXPERIMENTAL
Intervention: CPSG 5 g per day for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Starch granule (control) for 2 weeks
Number of subjects: 80
Study: 17457013

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 24
Study: 15105217

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gabapentin 1200 mg and Placebo
Number of subjects: 50
Study: 11298484

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (Aldara)
Number of subjects: 0
Study: 9749654

Group type: EXPERIMENTAL
Intervention: Usual drug therapy + spa therapy (6 days a week for 3 consecutive weeks)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual drug therapy
Number of subjects: 224
Study: 7835381

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3067695

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (no Vitamin A supplementation)
Number of subjects: 206
Study: 31696347

Group type: EXPERIMENTAL
Intervention: Blinding and randomization
Number of subjects: 0
Study: 30670268

Group type: EXPERIMENTAL
Intervention: Lemon Balm essential oil
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (Sunflower oil)
Number of subjects: 49
Study: 27404165

Group type: EXPERIMENTAL
Intervention: Engineered skin substitutes (ESS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Split-thickness autograft (AG)
Number of subjects: 15
Study: 25756936

Group type: EXPERIMENTAL
Intervention: Trifecta
Number of subjects: 22

Group type: COMPARATOR
Intervention: Freestyle
Number of subjects: 22
Study: 23963030

Group type: EXPERIMENTAL
Intervention: Intra-arterial octreotide (5 mL 500µg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (5 mL 0.9% saline solution)
Number of subjects: 25
Study: 20798960

Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female caregivers
Number of subjects: 0
Study: 19652648

Group type: EXPERIMENTAL
Intervention: Psychosexual therapy combined with pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional-sexological treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychological interventions
Number of subjects: 0
Study: 17684213

Group type: EXPERIMENTAL
Intervention: Nutributter (NB)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Nutritabs (NT)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Sprinkles (SP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 313
Study: 15324524

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Comparison between Donepezil and Placebo
Number of subjects: 190
Study: 10707475

Group type: EXPERIMENTAL
Intervention: Asthma telemedicine system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9586489

Group type: EXPERIMENTAL
Intervention: Bite-elevating appliance (BEA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo appliance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline biting in habitual occlusion
Number of subjects: 20
Study: 7902766

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3816920

Group type: EXPERIMENTAL
Intervention: Motapizone (8.8 +/- 1.8 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril (40 +/- 13 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dihydralazine (25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prazosin (4.5 +/- 1.1 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30329160

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 6814

Group type: COMPARATOR
Intervention: 3-dimensional conformal radiation therapy (3DCRT)
Number of subjects: 6814
Study: 26369274

Group type: EXPERIMENTAL
Intervention: DentalVibe (DV) Injection Comfort System
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Syringe (TS)
Number of subjects: 60
Study: 23826753

Group type: EXPERIMENTAL
Intervention: 12-month exercise program
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 158
Study: 22856494

Group type: EXPERIMENTAL
Intervention: Tracked patients with R‐IVCF
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (previously placed R‐IVCF)
Number of subjects: 93
Study: 20571252

Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candidate gene approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GWAS
Number of subjects: 0
Study: 18800957

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg PO BID
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 15785917

Group type: EXPERIMENTAL
Intervention: Oral appliance with mandible advance (12 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral appliance without mandible advance (12 patients)
Number of subjects: 24
Study: 12719065

Group type: EXPERIMENTAL
Intervention: Self-administered health status questionnaire
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: No comorbidities identified by the questionnaire
Number of subjects: 19250
Study: 10875161

Group type: EXPERIMENTAL
Intervention: Rufloxacin (200 mg single oral dose three hours before surgery)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg bid until catheter removal)
Number of subjects: 202
Study: 8828539

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y (20 nmol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oxymetazoline hydrochloride (20 nmol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline solution (NaCl 0.9%)
Number of subjects: 13
Study: 1391958

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: OKY-046 400 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg (3 hours after administration)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg (5 days of intake)
Number of subjects: 4
Study: 4011672

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 31
Study: 30921401

Group type: EXPERIMENTAL
Intervention: Antibiotic impregnated CVCs
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Heparin bonded CVCs
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Standard CVCs
Number of subjects: 1485
Study: 29361294

Group type: EXPERIMENTAL
Intervention: CaP bone cement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corticocancellous bone graft
Number of subjects: 20
Study: 26585292

Group type: EXPERIMENTAL
Intervention: Supportive educational nursing care programme (12 weeks, including fatigue assessment, education, coaching self-care, and evaluation)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Supportive educational nursing care programme
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study: 24972963

Group type: EXPERIMENTAL
Intervention: Compression-Adjusted Ventilation (CAV)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional Ventilation (CV)
Number of subjects: 97
Study: 22026446

Group type: EXPERIMENTAL
Intervention: Warfarin re-administration 3 days after burr hole drainage to reach target INR range of 1.7-2.5
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Warfarin re-administration 3 days after burr hole drainage
Number of subjects: 20
Study: 21443132

Group type: EXPERIMENTAL
Intervention: Total resection of lesser curvature with D2 lymph node dissection (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subtotal gastrectomy with D2 lymph node dissection (Group B)
Number of subjects: 120
Study: 17645678

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 16160759

Group type: EXPERIMENTAL
Intervention: Project ALERT drug prevention program
Number of subjects: 1649
Study: 11711839

Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Number of subjects: 69
Study: 9383690

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.6 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA, 10 mg)
Number of subjects: 33
Study: 7900456

Group type: EXPERIMENTAL
Intervention: alprazolam (anxiolytic)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: fluoxetine (antidepressant)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: combined chemotherapy with tranquilizers, antidepressants, neuroleptics
Number of subjects: 65
Study: 2452920

Group type: EXPERIMENTAL
Intervention: Indoramin (50 mg daily for 8 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indoramin (acute administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indoramin (chronic administration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2186650

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 100
Study: 1005577

Group type: EXPERIMENTAL
Intervention: Information leaflet about medication
Number of subjects: 160

Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 160
Study: 31743984

Group type: EXPERIMENTAL
Intervention: Superimposed neuromuscular electrical stimulation (NMES) combined with strengthening exercises
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standardized rehabilitation program alone
Number of subjects: 27
Study: 31870048

Group type: EXPERIMENTAL
Intervention: MIPPO under arthroscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 60
Study: 28828487

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 158
Study: 26001437

Group type: EXPERIMENTAL
Intervention: 100kVp spectral shaping chest CT using a tin filter on a 3rd generation DSCT
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100kVp chest CT on a 2nd generation DSCT without tin filter
Number of subjects: 60
Study: 22776142

Group type: EXPERIMENTAL
Intervention: EEA stapler (Covidien)
Number of subjects: 135

Group type: COMPARATOR
Intervention: PPH stapler (Ethicon EndoSurgery)
Number of subjects: 135
Study: 21835294

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 0
Study: 18995887

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 16707747

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Epirubicin, and Fluorouracil (CEF)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF)
Number of subjects: 710
Study: 14630985

Group type: EXPERIMENTAL
Intervention: T(3) 0.5 microg/kg plus daily T(4) during 6 weeks (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo T(3) and T(4) during 6 weeks (Group B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo T(3) and placebo T(4) (Group C)
Number of subjects: 31
Study: 11694816

Group type: EXPERIMENTAL
Intervention: HFA-BDP AH 800 microg x day(-1)
Number of subjects: 209

Group type: COMPARATOR
Intervention: BUD TH 1,600 microg x day(-1)
Number of subjects: 209
Study: 9216973

Group type: EXPERIMENTAL
Intervention: Diet-only group (D; n = 8)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diet+aerobic endurance exercise training group (DE; n = 9)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diet+aerobic endurance exercise training+strength training group (DES; n = 8)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (Con; n = 6)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All dietary groups (D, DE, DES)
Number of subjects: 31
Study: 7967419

Group type: EXPERIMENTAL
Intervention: Induction therapy including prednisone, vincristine (VCR), daunorubicin, L-asparaginase (L-ASP), cyclophosphamide (CP), cytarabine (ARA-C), 6-mercaptopurine (6-MP), and intrathecal methotrexate (MTX), followed by consolidation and maintenance up to 24 months.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with < 70% tumor regression at day 33 of induction.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surgical resection for patients with > 70% tumor regression at day 33 but a persistent mass at the end of induction.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Consolidation therapy for patients with a completely necrotic residual mass.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with active residual lymphoma.
Number of subjects: 80
Study: 2441167

Group type: EXPERIMENTAL
Intervention: 1 or 2 mg terazosin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 or 2 mg prazosin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28071133

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 27180224

Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominal sacrocolpopexy (LASC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Robotic abdominal sacrocolpopexy (RASC)
Number of subjects: 78
Study: 25914474

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg daily for 48 weeks
Number of subjects: 305

Group type: COMPARATOR
Intervention: Lamivudine (LAM) 100 mg daily for 48 weeks
Number of subjects: 305
Study: 23881958

Group type: EXPERIMENTAL
Intervention: Simvastatin plus extended-release niacin (ERN) (1500-2000 mg/d)
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Simvastatin plus matching placebo
Number of subjects: 3414
Study: 20494761

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine phacoemulsification (Control)
Number of subjects: 41
Study: 18204417

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) co-administered with other bipolar medications
Number of subjects: 1305
Study: 17010869

Group type: EXPERIMENTAL
Intervention: Injector implantation of foldable intraocular lenses (IOLs)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Forceps implantation of foldable intraocular lenses (IOLs)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Preoperative conjunctival samples
Number of subjects: 96

Group type: COMPARATOR
Intervention: Postoperative conjunctival samples
Number of subjects: 96
Study: 12962775

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 4 weeks (W4)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg for 4 weeks (W8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 23
Study: 11529301

Group type: EXPERIMENTAL
Intervention: Statistical methods for quantitative outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical methods for qualitative or categorical outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement of paper quality submitted to the European Respiratory Journal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insight into interpretation of results for readers
Number of subjects: 0
Study: 8976948

Group type: EXPERIMENTAL
Intervention: iodixanol (320 mg I/ml)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: iodixanol (300 mg I/ml)
Number of subjects: 81

Group type: COMPARATOR
Intervention: iopromide (300 mg I/ml)
Number of subjects: 81
Study: 7966077

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) 40 IU
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 60 mg
Number of subjects: 31
Study: 3034621

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.6, 1.6 and 4.0 ng kg‐1 min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.6, 1.6 and 4.0 ng kg‐1 min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxazosin (0.1 microgram kg min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine (1.0 microgram kg min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of doxazosin and yohimbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyramine (0.25, 0.50 and 1.25 micrograms kg‐1 min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP, ‐40 mmHg for 5 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (opposite arm during LBNP)
Number of subjects: 0
Study: 31185379

Group type: EXPERIMENTAL
Intervention: Combination of rheumatoid factor, matrix metalloproteinase‐9 and total homocysteine
Number of subjects: 638
Study: 26621634

Group type: EXPERIMENTAL
Intervention: 20-µg vitamin D3 daily for 12 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 25744062

Group type: EXPERIMENTAL
Intervention: Sucrose (post-education in Phase 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No sucrose (Phase 3)
Number of subjects: 50
Study: 23768267

Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine
Number of subjects: 1143

Group type: COMPARATOR
Intervention: HAV vaccine
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 1143
Study: 21697134

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19301232

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (50% lispro, 50% insulin lispro protamine suspension) pre-breakfast and lispro mix 25 (25% lispro, 75% insulin lispro protamine suspension)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Glibenclamide plus bedtime neutral protamine Hagedorn (NPH) insulin
Number of subjects: 135
Study: 17015784

Group type: EXPERIMENTAL
Intervention: Individualized traditional Chinese acupuncture
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Standardized acupuncture at preselected points
Number of subjects: 192

Group type: COMPARATOR
Intervention: Invasive sham acupuncture
Number of subjects: 192
Study: 12766915

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic and rehabilitation program
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 190
Study: 11035136

Group type: EXPERIMENTAL
Intervention: 4162W94 10 mg i.v. for 5 consecutive days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4162W94 30 mg i.v. for 5 consecutive days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4162W94 100 mg i.v. for 5 consecutive days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4162W94 300 mg i.v. for 5 consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 8622092

Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone (IRH)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone (SRH)
Number of subjects: 95
Study: 1599115

Group type: EXPERIMENTAL
Intervention: ORG-9426 (600 micrograms/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ORG-9426 (120 micrograms/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ORG-9426 (240 micrograms/kg)
Number of subjects: 62
Study: 3976556

Group type: EXPERIMENTAL
Intervention: 200 micrograms Cr in the form of chromic chloride
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 31600343

Group type: EXPERIMENTAL
Intervention: ART at any CD4 cell count with enhanced support for ART and substance use treatment
Number of subjects: 449
Study: 30025227

Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program (MRP) + usual care (UC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 32
Study: 27484880

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/day
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg/day or 10 mg/week
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Tamoxifen (both doses)
Number of subjects: 367
Study: 22458386

Group type: EXPERIMENTAL
Intervention: Fluorine-synthetic fiber socks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cotton socks
Number of subjects: 20
Study: 21750485

Group type: EXPERIMENTAL
Intervention: rFVIIa (100 mcg/Kg b.w.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20117669

Group type: EXPERIMENTAL
Intervention: Binaural auditory beats
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham audio program (control)
Number of subjects: 20
Study: 17941358

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (including tetracyclines, subantimicrobial dose doxycycline, macrolides, trimethoprim-sulfamethoxazole, cephalosporins, and fluoroquinolones)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical and oral retinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study: 15756901

Group type: EXPERIMENTAL
Intervention: Grommets intervention (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior beliefs of ENT‐surgeons (measured before the trial)
Number of subjects: 0
Study: 11984098

Group type: EXPERIMENTAL
Intervention: Magnetic therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11